01808nam a2200397 i 4500001001300000003000600013005001700019007001400036008004100050040002300091042000800114043001200122050002000134074001900154086002900173110008100202245017200283264006000455264010100515300004500616336000800661337001600669338001900685490002300704500003600727500002500763504004100788533010600829650005300935610002700988650004301015655003301058776013001091776012901221810006001350ocn948805053OCoLC20160815075448.0he bmb024bbca160506s2015    dcua    bb   f000 0 eng c  aGPObengerdacGPO  apcc  an-us---14aKF26b.V4 2014f  a1046-A-02 (MF)0 aY 4.V 64/4:S.HRG.113-7461 aUnited States.bCongress.bSenate.bCommittee on Veterans' Affairs,eauthor.10aHepatitis C and veterans :bhearing before the Committee on Veterans' Affairs, United States Senate, One Hundred Thirteenth Congress, second session, December 3, 2014. 1aWashington :bU.S. Government Publishing Office,c2015. 2aWashington, DC :bFor sale by the Superintendent of Documents, U.S. Government Publishing Office  aiii, 46 pages :billustrations ;c24 cm.  btxt  bh2rdamedia  bhe2rdacarrier1 aS. hrg. ;v113-746  aShipping list no.: 2016-0109-M.  aCRDP Project record.  aIncludes bibliographical references.  aMicrofiche.b[Washington, D.C.] :cU.S. Government Printing Office,d[2015]e1 microfiche : negative. 0aHepatitis CxChemotherapyzUnited StatesxCosts.20aGilead Sciences (Firm) 0aVeteransxMedical carezUnited States. 7aLegislative hearings.2lcgft08iOnline version:aUnited States. Congress. Senate. Committee on Veterans' Affairs.tHepatitis C and veteransw(OCoLC)93352833208iPrint version:aUnited States. Congress. Senate. Committee on Veterans' Affairs.tHepatitis C and veteransw(OCoLC)9337600501 aUnited States.bCongress.bSenate.tS. hrg. ;v113-746.